S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Haemonetics Stock Forecast, Price & News

+2.14 (+3.28%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
457,830 shs
Average Volume
476,536 shs
Market Capitalization
$3.45 billion
P/E Ratio
Dividend Yield
Price Target

Haemonetics Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.50 Rating Score
7.5% Upside
$72.40 Price Target
Short Interest
3.59% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.66mentions of Haemonetics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$490.40 K Sold Last Quarter
Proj. Earnings Growth
From $2.72 to $2.98 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.86 out of 5 stars

Medical Sector

668th out of 1,428 stocks

Surgical & Medical Instruments Industry

76th out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

Haemonetics logo

About Haemonetics (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Stock News Headlines

Haemonetics (NYSE:HAE) Upgraded by StockNews.com to "Buy"
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Supplies
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
$43.38 million
Pretax Margin


Sales & Book Value

Annual Sales
$993.20 million
Cash Flow
$4.57 per share
Book Value
$14.66 per share


Free Float
Market Cap
$3.45 billion

Social Links

Haemonetics Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Haemonetics stock.
View analyst ratings for Haemonetics
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2022?

6 brokerages have issued 12-month price targets for Haemonetics' stock. Their HAE stock forecasts range from $59.00 to $80.00. On average, they expect Haemonetics' stock price to reach $72.40 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Haemonetics
or view top-rated stocks among Wall Street analysts.

How has Haemonetics' stock price performed in 2022?

Haemonetics' stock was trading at $53.04 at the beginning of the year. Since then, HAE stock has increased by 26.9% and is now trading at $67.32.
View the best growth stocks for 2022 here

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Haemonetics

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Tuesday, May, 10th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.05. The medical instruments supplier had revenue of $265 million for the quarter, compared to analysts' expectations of $257.11 million. Haemonetics had a trailing twelve-month return on equity of 18.57% and a net margin of 4.37%. The firm's revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.46 earnings per share.
View Haemonetics' earnings history

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY 2023 earnings guidance on Tuesday, June, 7th. The company provided EPS guidance of $2.50-$2.90 for the period, compared to the consensus estimate of $2.75. The company issued revenue guidance of $1.04 billion-$1.08 billion, compared to the consensus revenue estimate of $1.03 billion.

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher A. Simon, CEO, Pres & Director (Age 58, Pay $2.03M) (LinkedIn Profile)
  • Ms. Anila Lingamneni, Exec. VP & CTO (Age 54, Pay $845.33k)
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec. (Age 50, Pay $815.71k) (LinkedIn Profile)
  • Mr. William P. Burke, Advisor (Age 53, Pay $925.86k) (LinkedIn Profile)
  • Mr. Josep Lluis Llorens, Exec. VP of Global Manufacturing & Supply Chain (Age 59, Pay $700.75k)
  • Mr. James C. D'Arecca CPA, Exec. VP & CFO (Age 51)
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 45)
  • Ms. Olga Guyette, Director of Investor Relations
  • Carla Burigatto, VP of Communications
  • Mr. Francis Tan, Sr. VP of Corp. Devel. & Planning

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among Haemonetics' employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), APA (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $67.32.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $3.45 billion and generates $993.20 million in revenue each year. The medical instruments supplier earns $43.38 million in net income (profit) each year or $0.839990 on an earnings per share basis.

How many employees does Haemonetics have?

Haemonetics employs 2,821 workers across the globe.

When was Haemonetics founded?

Haemonetics was founded in 1971.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for Haemonetics is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.